lysylproline has been researched along with glucagon-like peptide 1 in 1 studies
| Studies (lysylproline) | Trials (lysylproline) | Recent Studies (post-2010) (lysylproline) | Studies (glucagon-like peptide 1) | Trials (glucagon-like peptide 1) | Recent Studies (post-2010) (glucagon-like peptide 1) |
|---|---|---|---|---|---|
| 10 | 0 | 2 | 9,484 | 1,208 | 6,374 |
| Protein | Taxonomy | lysylproline (IC50) | glucagon-like peptide 1 (IC50) |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | Homo sapiens (human) | 0.0051 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batra, Y; Jaglan, S; Kaur, B; Rani, S; Singh, P | 1 |
1 other study(ies) available for lysylproline and glucagon-like peptide 1
| Article | Year |
|---|---|
Proline based rationally designed peptide esters against dipeptidyl peptidase-4: Highly potent anti-diabetic agents.
Topics: Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Esters; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Hypoglycemic Agents; Oligopeptides; Proline; Sitagliptin Phosphate | 2022 |